CHINARES PHARMA (03320) announces annual performance, with a net profit attributable to shareholders of 4.045 billion yuan, a year-on-year increase of 20.73%. Both revenue and profits have achieved double growth.

CHINARES PHARMA (03320) announced its annual performance for the year ending December 31, 2025, with a total revenue of RMB 269.574 billion, a year-on-year growth of 4.62%; attributable net profit to shareholders of RMB 4.045 billion, a year-on-year growth of 20.73%; earnings per share of 0.64 yuan; and a final dividend of 0.122 yuan. In 2025, the Group actively served national strategies, focused on cultivating new productive forces in the pharmaceutical field, promoted the layout of strategic emerging industries, and various measures to promote research and development innovation. The Group strengthened mergers and acquisitions and product introductions, improved the resilience and safety of the supply chain, and enhanced the efficiency of digital transformation and green low-carbon development. Against the backdrop of intensified competition and downward pressure in the pharmaceutical industry, the Group achieved double growth in revenue and profit in 2025, with revenue growth outperforming the industry average during the "14th Five-Year Plan" period. The Group ranks among the top in the comprehensive influence of the domestic pharmaceutical industry, is a comprehensive pharmaceutical industry leader with both manufacturing and distribution advantages, ranks third in terms of overall operating scale in the industry, second in the pharmaceutical manufacturing business among the top 100 pharmaceutical industries, and third in the pharmaceutical distribution business. During the reporting period, the Group's brands achieved outstanding honors, with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. ("China Resources Sanjiu Medical & Pharmaceutical") awarded the first prize of the Ministry of Education's Excellent Scientific Research Achievements Award, and rated as the highest "benchmark" level by the State Council's SASAC "Science and Technology Reform" for three consecutive years; "Jiangzhong" and "Dong-E-E-Jiao" were selected for the Ministry of Industry and Information Technology's first batch of China Famous Consumer Brands list; China Resources Double-Crane Pharmaceutical Co., Ltd. ("China Resources Double-Crane Pharmaceutical") was rated as an "excellent case of national health enterprise construction"; China Resources Sanjiu Medical & Pharmaceutical, China Resources Double-Crane Pharmaceutical, China Resources Jiangzhong Pharmaceutical Co., Ltd. ("China Resources Jiangzhong Pharmaceutical"), and Dong-E-E-Jiao Co., Ltd. were collectively selected as "excellent intelligent factories" by the Ministry of Industry and Information Technology, showcasing the Group's multi-level and multi-dimensional brand influence.